BPC-157 + Ipamorelin Stack: Complete Protocol, Doses, and Timing

What the Evidence Base Actually Says About This Stack

Combining BPC-157 with Ipamorelin has a following in sports-medicine and anti-aging circles, but the evidence picture is uneven. No peer-reviewed randomized controlled trial has evaluated the two peptides together in humans. What exists is a body of animal pharmacology data for each compound individually, mechanistic plausibility arguments for stacking them, and practitioner-reported clinical observations.

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide derived from a fragment of human gastric juice protein. Rodent studies show it accelerates tendon-to-bone healing, promotes angiogenesis, and modulates nitric oxide synthesis. A 2018 review in the Journal of Physiology and Pharmacology summarized BPC-157's effects on growth factors and nitric oxide pathways in murine models, noting consistent pro-angiogenic activity across injury models 1.

Ipamorelin is a pentapeptide GHSR (growth hormone secretagogue receptor) agonist. Unlike GHRP-6, it does not significantly raise cortisol or prolactin at therapeutic doses. A key preclinical paper published in Growth Hormone and IGF Research confirmed Ipamorelin's selectivity for GH release without the adrenocorticotropic hormone (ACTH) side-effect profile seen with earlier secretagogues 2.

Why the Evidence Gap Matters Clinically

Because no human trial exists for this specific combination, every dosing recommendation in this article derives from single-agent human data, animal pharmacology, and structured clinical observation. Practitioners should treat any outcome claim as hypothesis-level, not established fact.

The FDA has not approved either peptide for human therapeutic use. Both are classified as research chemicals. The FDA's position on compounded peptides issued in 2023 placed several GHRP-class secretagogues and BPC-157 outside the category of bulk drug substances that may be used in compounding 3.

What Animal Data Suggests About Combined Use

Rat studies on BPC-157 consistently show tissue-healing benefit in musculoskeletal injury models. A 2019 study in Molecules examined BPC-157 in Achilles tendon transection models and reported statistically significant improvements in tensile strength recovery compared with saline control (P<0.01) 4. Ipamorelin's contribution in a stacking context would theoretically come from GH-mediated collagen synthesis upregulation. GH increases IGF-1, and IGF-1 upregulates collagen type I and III gene expression in fibroblasts 5. The mechanistic case for combination is plausible but unproven in combined administration.

Mechanisms of Action: How Each Peptide Works

Understanding why practitioners stack these two compounds requires understanding what each one does at the receptor level.

BPC-157: Tissue Repair Through Multiple Pathways

BPC-157 does not bind a single identified receptor. Its effects appear mediated through several overlapping pathways. In gastrointestinal tissue, it upregulates expression of the growth hormone receptor, which may partially explain why its effects intersect with GH biology 6. It also activates FAK (focal adhesion kinase) and paxillin signaling, which drives cell migration essential for wound closure 7.

Nitric oxide modulation is another documented mechanism. BPC-157 appears to rescue nitric oxide production in endothelium damaged by NOS inhibitors, restoring vascular tone in animal models 8. This vascular activity may explain its observed effect on blood pressure in stress-exposure rodent experiments.

Ipamorelin: Selective GH Pulse Amplification

Ipamorelin binds the GHSR-1a receptor in the pituitary. It mimics ghrelin's GH-releasing action while producing minimal effect on other anterior pituitary hormones at doses up to 300 mcg/kg in animal studies. That selectivity profile was quantified in the original Raun et al. (1998) paper, which remains the foundational pharmacology reference for this molecule 2.

GH pulses stimulate hepatic IGF-1 production. IGF-1 then acts on peripheral tissues, muscle, bone, tendon, cartilage, to increase protein synthesis and reduce proteolysis. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that GH replacement in GH-deficient adults increased lean body mass by an average of 2.1 kg and reduced fat mass by 2.7 kg over 6 months of treatment 9. Ipamorelin's physiologic GH stimulation is milder than exogenous GH, but the pathway is the same.

The Complementarity Argument

BPC-157 acts locally at injury sites through cell-migration and angiogenic signals. Ipamorelin acts systemically through pituitary GH release. These are distinct and non-overlapping upstream mechanisms, which is the core rationale practitioners use to justify combining them. One acts peripherally on damaged tissue; the other activates a systemic anabolic axis. Neither mechanistically competes with the other.

Dosing Protocol: BPC-157 + Ipamorelin

Dosing recommendations below are synthesized from animal pharmacology, published single-agent human studies, and structured clinical observation. They represent the range most commonly reported in supervised clinical contexts, not FDA-approved dosing.

BPC-157 Dosing

The most frequently cited dose range for BPC-157 in research contexts is 250 to 500 mcg per injection. Most practitioners administer once or twice daily. Animal studies use weight-adjusted dosing of approximately 2 mcg/kg to 10 mcg/kg; for a 70 kg human, that extrapolates to 140 to 700 mcg/day. The 250 mcg twice-daily schedule (500 mcg/day total) sits near the middle of this range.

Injection site selection depends on the target. For systemic effects, subcutaneous injection into abdominal fat is standard. For localized tendon or joint repair, practitioners sometimes administer intramuscularly near the affected tissue, though this practice lacks controlled human evidence.

Ipamorelin Dosing

Ipamorelin is typically dosed at 100 to 300 mcg per injection, administered two to three times daily. Because Ipamorelin works by stimulating GH pulses, timing relative to the body's natural pulsatile secretion pattern matters. GH pulses peak shortly after sleep onset and, to a lesser degree, during fasted states. Dosing at bedtime, and optionally upon waking in a fasted state, aligns administration with these windows.

A fasting period of at least 90 minutes before and after injection is recommended in clinical practice to avoid the GH-blunting effect of postprandial insulin elevation. Insulin and GH are physiologically antagonistic at the level of somatostatin regulation 10.

Sample 8-Week Stack Schedule

| Time of Day | Compound | Dose | Notes | |---|---|---|---| | Upon waking (fasted) | Ipamorelin | 200 mcg | Subcutaneous; wait 90 min before eating | | Mid-morning | BPC-157 | 250 mcg | Subcutaneous or IM near target tissue | | Pre-bed (2+ hrs post-meal) | Ipamorelin | 200 mcg | Subcutaneous; aligns with nocturnal GH pulse | | Pre-bed (same injection session) | BPC-157 | 250 mcg | Can be drawn into the same syringe if same diluent |

Cycle length: 8 weeks on, followed by a minimum 4-week off-period. Some practitioners extend to 12 weeks for musculoskeletal injury protocols, then taper Ipamorelin dose to 100 mcg for the final 2 weeks before stopping.

Reconstitution and Storage

Both peptides are supplied as lyophilized (freeze-dried) powder and require reconstitution before injection.

Reconstitution Steps

Bacteriostatic water (BAC water) is the preferred diluent for both compounds. BAC water contains 0.9% benzyl alcohol as a preservative, extending stability of the reconstituted peptide to approximately 28 days when refrigerated at 2 to 8 degrees Celsius. Standard sterile 0.9% sodium chloride is acceptable for immediate single-use preparation but provides no preservative protection.

A common reconstitution target for BPC-157 is 500 mcg/mL (1 mg vial reconstituted in 2 mL BAC water). For a 250 mcg dose, draw 0.5 mL (50 units on an insulin syringe). For Ipamorelin at 2 mg/vial reconstituted in 2 mL BAC water, the concentration is 1,000 mcg/mL. A 200 mcg dose requires 0.2 mL (20 units on an insulin syringe).

Store lyophilized vials at 2 to 8 degrees Celsius, protected from light. Reconstituted peptides degrade faster at room temperature; discard any vial left unrefrigerated for more than 4 hours.

Injection Technique

Use a 29 or 31 gauge, 0.5-inch insulin syringe for subcutaneous injections. Pinch a fold of abdominal or thigh skin, insert at 45 degrees, inject slowly, and apply light pressure after withdrawal. Rotate injection sites to reduce local irritation. Alcohol-swab the vial septum and injection site before each use. Proper aseptic technique reduces infection risk at the injection site 11.

Safety Profile and Side Effects

BPC-157 Safety Data

No human safety trial with formal adverse event reporting has been completed for BPC-157. The available animal data show a favorable acute toxicity profile; a 2011 Current Pharmaceutical Design review noted no observed adverse effects in rats at doses up to 10 mcg/kg administered chronically 12. The most commonly reported side effects in self-reported human use are nausea (particularly with oral or sublingual administration), mild dizziness after injection, and transient warmth at the injection site.

A theoretical concern exists around BPC-157's pro-angiogenic activity in the context of pre-existing neoplasia. Animal data suggest BPC-157 upregulates VEGF expression 13. Anyone with a personal or family history of hormone-sensitive or angiogenesis-dependent cancers should not use this compound.

Ipamorelin Safety Data

Ipamorelin's safety advantage over earlier GHRPs is its minimal effect on cortisol and prolactin. At doses up to 300 mcg in human volunteers, Raun et al. (1998) did not observe significant ACTH or cortisol elevation 2. The most commonly observed side effects are mild and transient: flushing, tingling, and headache within 30 minutes of injection. These typically resolve without intervention.

Sustained GH stimulation carries the same theoretical risks as exogenous GH use: fluid retention, carpal tunnel syndrome, and potential effects on insulin sensitivity. The Endocrine Society's clinical practice guideline on GH use in adults notes that "adverse effects of GH therapy, including edema, arthralgia, and glucose intolerance, are dose-dependent and largely reversible upon dose reduction" 14. These cautions apply to Ipamorelin by mechanism, even though its GH pulse amplitude is lower than exogenous HGH.

Who Should Not Use This Stack

This combination is contraindicated in the following groups: active malignancy of any type, pregnancy, breastfeeding, pediatric patients, and individuals with acromegaly or any condition causing GH excess. Anyone with a history of pituitary tumors should avoid GH secretagogues entirely. Baseline IGF-1 measurement is recommended before starting Ipamorelin to rule out pre-existing GH excess (normal adult IGF-1 range: approximately 100 to 300 ng/mL, age-dependent) 15.

Monitoring During the Stack

Labs to Check Before Starting

Order these labs before the first injection: IGF-1 (baseline), fasting glucose, HbA1c, complete metabolic panel, and a CBC. If the patient is also on testosterone replacement or other anabolic compounds, add a full lipid panel and hematocrit.

Labs to Check at Week 4 and Week 8

Recheck IGF-1 at week 4. Target IGF-1 should remain within the age-adjusted reference range for the patient. If IGF-1 rises above the upper limit of normal, reduce Ipamorelin dose by 50 mcg per injection or eliminate one of the daily administrations. Recheck fasting glucose at week 8 to assess for any insulin sensitivity shift. A clinical review in the Journal of Clinical Endocrinology and Metabolism found that GH excess states, even mild ones, reduced peripheral insulin sensitivity by approximately 15 to 25% through hepatic glucose output upregulation 16.

Subjective Monitoring Checkpoints

Patients should log sleep quality, joint comfort, and energy levels weekly. BPC-157's tissue repair effects, if present, are reported subjectively as reduced pain and improved range of motion in the 3 to 6 week window. Ipamorelin's effects on sleep quality and body composition may begin emerging at week 4 to 6, consistent with the time required for IGF-1 levels to plateau following a new secretagogue regimen.

Comparing This Stack to Related Peptide Protocols

Practitioners sometimes ask whether to use BPC-157 alone, Ipamorelin alone, or a different GH secretagogue pairing such as CJC-1295 with Ipamorelin.

CJC-1295 (with DAC) produces a sustained elevation in baseline GH rather than discrete pulses, because the drug affinity complex (DAC) extends its half-life to approximately 8 days. A 2006 study in the Journal of Clinical Endocrinology and Metabolism found that CJC-1295 with DAC (2 mg, single dose) elevated mean GH levels 2 to 10-fold for up to 6 days and IGF-1 by 1.5 to 3-fold for 9 to 11 days 17. The CJC-1295/Ipamorelin combination is therefore preferred when the primary goal is sustained anabolic GH elevation. The BPC-157/Ipamorelin stack is more commonly chosen when active tissue injury is the primary indication, because BPC-157 adds a direct tissue-protective signal that CJC-1295 does not.

For purely musculoskeletal recovery without a GH component, TB-500 (Thymosin Beta-4) is sometimes substituted for Ipamorelin. TB-500 promotes actin polymerization and cell migration through a distinct pathway. BPC-157 and TB-500 are also commonly stacked and represent a different but overlapping recovery-focused protocol.

Legal and Regulatory Context

Both BPC-157 and Ipamorelin are research chemicals in the United States. Neither has an FDA-approved indication. The FDA's 2023 guidance placed BPC-157 and several GHRP-class peptides on the list of substances that cannot be used in compounded preparations under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act 3.

In practical terms, this means licensed U.S. Compounding pharmacies can no longer legally compound these peptides for clinical administration. Patients sourcing these compounds from research-chemical vendors operate outside any regulatory oversight of product purity or concentration. Third-party certificate-of-analysis (CoA) testing from an independent laboratory is the minimum quality check a patient can perform, though it does not guarantee sterility.

The World Anti-Doping Agency (WADA) prohibits Ipamorelin under its GH secretagogue category, and BPC-157 falls under its peptide hormones and related substances prohibition. Athletes subject to WADA testing should not use either compound 18.